Community Practice Connections: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients

Community Practice Connections: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients is organized by Physicians' Education Resource LLC (PER) and will be held from Aug 30, 2018 - Aug 30, 2019.

The target audience for this medical event is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate. This CME Conference has been approved for a maximum of 1.5 Credits.

Description:
A great deal of progress has been made in the understanding of the mechanistic underpinnings for the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer. As the volume of evidence supporting the role of PARP inhibitors continues to accumulate, it is important for you to be able to apply clinical data to the development of treatment paradigms that maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.
 
To help you optimize the management of your patients with breast cancer, we have developed an exciting educational activity that will highlight the latest clinical evidence pertaining to the use of PARP inhibitors. This activity features commentary from leading experts in the management of patients with breast cancer, who will provide their perspectives on the rationale for PARP inhibitor utilization, key aspects of recent clinical studies, strategies to mitigate and manage predictable adverse events, and future directions for PARP inhibitor therapy.

Learning Objectives
At the conclusion of this activity, you should be better prepared to:
• Outline the mechanistic rationale that underlies the application of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition approaches for the management of breast cancer
• Apply key evidence from PARP inhibition trials in breast cancer, and report recent findings from investigations evaluating potential new roles for these approaches
• Summarize strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies
• Identify strategies that are being explored to maximize the efficacy of PARP inhibition in the treatment of patients with breast cancer